Dan Tang
Ruo-Yu Wang1†
Ke-Wei Sun
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Hepatology, The First Hospital of Hunan University of Traditional Chinese Medicine, Changsha, China
- 2Academic Affairs Office, Hunan University of Traditional Chinese Medicine, Changsha, China
A Corrigendum on
Network pharmacology-based prediction of active compounds in the Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental supportin vitro and in vivo by Tang D, Wang R-Y, Sun K-W, Wu Y, Ding L and Mo Y (2022). Front. Pharmacol. 13:1003479. doi: 10.3389/fphar.2022.1003479
In the published article, there was an error in the Funding statement. The funding statement for the National Natural Science Foundation of China was displayed as “(8197152432 and 82104809).” The correct Funding statement appears below.
“Funding
This study was supported by the National Natural Science Foundation of China (81973833 and 82104809), and the Hunan University of Chinese Medicine Graduate student innovation topics (2020CX18).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: acute-on-chronic liver failure, Wenyang Jiedu Huayu formula, network pharmacology, atractylenolide I, rat hepatocytes, ACLF rat model
Citation: Tang D, Wang R-Y, Sun K-W, Wu Y, Ding L and Mo Y (2022) Corrigendum: Network pharmacology-based prediction of active compounds in Wenyang Jiedu Huayu formula acting on acute-on-chronic liver failure with experimental support in vitro and in vivo. Front. Pharmacol. 13:1105804. doi: 10.3389/fphar.2022.1105804
Received: 23 November 2022; Accepted: 24 November 2022;
Published: 01 December 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Tang, Wang, Sun, Wu, Ding and Mo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ke-Wei Sun, a2V3ZWlzdW41NTBAMTYzLmNvbQ==
†These authors have contributed equally to this work